Valiant Laboratories Limited — Important, 07-02-2025: General Updates

**Updates:**

The Board of Directors reviewed and approved the audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024. Standalone total income for this period stood at ₹3,589.46 Crore, a decrease from ₹4,051.52 Crore in the corresponding quarter last year. The company's standalone net profit fell to ₹160.01 Crore from ₹350.31 Crore year-on-year, affected by higher expenses, particularly in material costs. Consolidated financial results reflected total income of ₹3,681.11 Crore and a net profit of ₹234.51 Crore.

There's a positive outlook as the company’s operational structure remains stable, but investors should keep an eye on fluctuating material costs and their impact on profit margins moving forward. Overall, these results suggest a cautious but zero-in on recovery potential in subsequent quarters.